Funding Opportunity PAR-22-265 from the NIH Guide for Grants and Contracts. Reissue of PAR-17-096. The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be outstanding scientists equipped to pursue careers in neuroscience.

Funding Opportunity PAR-23-269 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

Funding Opportunity PAR-23-113 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide support for institutional research training programs in Alzheimers Disease/Alzheimers Disease-Related Dementias (AD/ADRD). These institutional research training programs should produce well-trained neuroscientists who leave the program with the research skills and scientific knowledge to make a significant contribution to research on AD/ADRD cognitive impairment and dementia. Programs should be designed to enhance the breadth and depth of training across the spectrum AD/ADRD research areas (e.g. AD, Vascular Contributions to Cognitive Impairment and Dementia (VCID), Lewy Body Dementia (LBD), Fronto-temporal Dementia (FTD) and mixed dementias) by incorporating didactic, research and career development components within this theme into a program that fosters exceptional research skills and knowledge. Programs may support basic, clinical and/or translational research. Programs supported by this FOA must include formal components to ensure a thorough understanding of experimental design, statistical principles and methodological approaches, analytical skills, and skills for communicating science, both orally and in writing, to a wide variety of audiences. All programs are expected to design and/or provide opportunities and activities that will foster the development of quantitative literacy and the application of quantitative approaches to the trainees' research. These training programs are intended to be 2 years in duration and support training of one or more of the following groups: dissertation stage predoctoral students in their 3rd and/or 4th year of graduate school, postdoctoral fellows and fellowship-stage clinicians. (NINDS does not support first or second year graduate students under this FOA).

Notice NOT-OD-23-093 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-104 from the NIH Guide for Grants and Contracts

Funding Opportunity PA-23-134 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is for investigators and institutions impacted by Hurricanes Fiona and Ian with active NIH grants to request: 1)a 24-month extension of the current budget period, with 12-months of funding at the same funding level as the current year of the grant and/or 2)a one-time administrative supplement of up to $150,000 in direct costs (excluding consortium facilities and administrative costs) to replace lost and/or damaged research resources; and/or 3)up to $250,000 to replace a single item of equipment so long as that request is accompanied by well-documented support for the need to replace that item of equipment; and/or 4)minor alternation and renovation to research facilities up to $500,000. Supplement requests will be routed to the appropriate NIH Institutes and Centers for consideration. The number of awards issued will depend on the number of applicants received and funneled through the review process. Benefits of this opportunity are restricted to applicants located in a county or parish where a major disaster has been declared under the Stafford Act as a result of Hurricanes Fiona and Ian. Grants at NIH-supported institutions impacted by Hurricanes Fiona and Ian will be eligible for both the funded extension and/or administrative supplements. If a grant has relocated or relocates prior to the award of the funded extension, the funded extension may be withdrawn. Applications submitted in response to this announcement will be considered for funding only with funds appropriated from the Consolidated Appropriations Act, 2023 (Public Law 117-328). This opportunity does not preclude additional requests for administrative supplements on other NIH grant programs or for these mechanisms. Institutes and Centers will still consider such requests on a case-by-case basis. These funds cannot duplicate nor overlap with reimbursement provided by FEMA, under a contract for insurance, or by self-insurance. Self-insurance is a forma

Notice NOT-MH-23-195 from the NIH Guide for Grants and Contracts

Notice NOT-MH-23-196 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-128 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program. This FOA aims to position innovative and validated methods for future clinical development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission.

Notice NOT-ES-23-009 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-RM-23-004 from the NIH Guide for Grants and Contracts. The NIH Directors Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigators research program or elsewhere. The NIH Directors Pioneer Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.

Notice NOT-AG-23-014 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-065 from the NIH Guide for Grants and Contracts

Notice NOT-HL-23-082 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-122 from the NIH Guide for Grants and Contracts. The NIH ?Research With Activities Related to Diversity (ReWARD) Program's overarching goal is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories.

Notice NOT-DK-23-014 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-009 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-23-019 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from single institutions or consortia of institutions to participate in the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network. The purpose of this FOA is to establish comprehensive, cooperative basic and translational research Centers to carry out in-depth research on prototype members of select virus families that have the potential to emerge as pandemic pathogens. The goal of these Centers will be to develop vaccine and monoclonal antibody strategies for prototype pathogen(s) that can be applied to closely related family members based on shared functional and structural properties. This FOA solicits for Centers proposing research on virus families from Flaviviridae and Togaviridae to be part of the ReVAMPP Network.

Funding Opportunity RFA-AI-23-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from single institutions or consortia of institutions to participate in the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network. The purpose of this FOA is to establish comprehensive, cooperative basic and translational research Centers to carry out in-depth research on prototype members of select virus families that have the potential to emerge as pandemic pathogens. The goal of these Centers will be to develop vaccine and monoclonal antibody strategies for prototype pathogen(s) that can be applied to closely related family members based on shared functional and structural properties. This FOA solicits for centers proposing research on virus families from Bunyavirales, Paramyxoviridae and Picornaviridae to be part of the ReVAMPP Network.

Funding Opportunity RFA-AI-23-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from single institutions or consortia of institutions to establish a Coordination and Data Sharing Center (CDSC) in support of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers. Together, the CDSC and ReVAMPP Centers will form the ReVAMPP Network. The purpose of the CDSC is to support, coordinate, and manage ongoing and planned activities within the ReVAMPP Network. The CDSC is expected to establish and maintain a collaborative ReVAMPP Network platform for data sharing as needed to harmonize reagents, assays, animal models and exchange knowledge on structure/function-based vaccine solutions and antigen/immunogen design as well as assess the utility of vaccine technology platforms for virus families studied under the ReVAMPP Centers. The CDSC is also expected to facilitate effective communications across the ReVAMPP Centers by scheduling, and managing all meetings, tracking overall network progress and outputs, developing opportunities for collaboration among the Centers such as establishing working groups, and under the direction of NIAID, collating information and facilitating exchange with other NIAID/NIH programs, U.S. Government (USG)partners, and other key stakeholders, including the World Health Organization (WHO), Bill and Melinda Gates Foundation (BMGF), and Coalition for Epidemic Preparedness Innovations (CEPI) among others as appropriate.